Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.
Clinical Trials
17
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2011
Active, not recruiting
1
5.9%
Completed
9
52.9%
Recruiting
1
5.9%
Terminated
6
35.3%
No approval data available
- UnitedHealthcare updated its policy to cover OMNI Surgical System procedures for mild to moderate open-angle glaucoma treatment, effective October 1, 2025, covering approximately 30 million patients. - A comprehensive meta-analysis of 2,379 eyes demonstrated that OMNI achieves treatment success in approximately 89% of patients with sustained IOP reductions and medication-free outcomes in 66-68% of cases. - The study confirmed OMNI's cost-effectiveness compared to market leader iStent inject, with superior quality-adjusted life years and favorable adverse event profile. - Economic analyses indicate OMNI provides 8.95 QALYs per patient over a lifetime horizon compared to 8.93 for iStent inject, attributed to its better safety profile.
- A cost-utility analysis published in Expert Review of Pharmacoeconomics and Outcomes Research shows TearCare System reduces per-patient annual costs by $903 compared to cyclosporine 0.05% for treating moderate to severe meibomian gland disease-associated dry eye. - The analysis revealed TearCare resulted in lower annual costs of $4,916 and higher quality-adjusted life years of 0.76, compared to cyclosporine's $5,819 costs and 0.74 QALYs over a one-year period. - TearCare patients experienced an incremental QALY gain of 0.014 while receiving two procedures annually, demonstrating both clinical and economic advantages over traditional cyclosporine therapy. - The study was conducted from a US healthcare payer perspective and confirmed TearCare's cost-saving advantage through robust scenario analyses that validated results across different clinical assumptions.
- Meta-analysis of 22 studies demonstrates significant long-term intraocular pressure reduction and decreased medication dependence using the OMNI® Surgical System for glaucoma treatment. - Real-world data from the IRIS® Registry confirms sustained effectiveness of standalone canaloplasty and trabeculotomy procedures over 36 months in primary open-angle glaucoma patients. - New analysis from the ROMEO Study reveals OMNI® achieves comparable pressure and medication reductions across mild, moderate, and advanced glaucoma cases.
